Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera – German real-world data (PaVe study)

/µl). There was almost no difference in the total number of thromboembolic events in JAK inhibitor naïve versus JAK inhibitor pretreated patients (3.1%, n = 5 versus 3.8%, n = 10). No new safety concerns were observed with ruxolitinib. Findings from this study in a real-world setting show that ruxolitinib is an effective and safe second-line treatment in PV patients.

Authors

Institutions

Publication Details

Journal
Annals of Hematology
Published
2026-05-12
DOI
https://doi.org/10.1007/s00277-026-06947-9
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera – German real-world data (PaVe study)

Martin Grießhammer, Rudolf Weide, Eva Gückel, Burkhard Schmidt et al.
Annals of Hematology
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera – German real-world data (PaVe study)

Martin Grießhammer, Rudolf Weide, Eva Gückel, Burkhard Schmidt, Michael Koenigsmann, Rudolf Schlag, Volker Baum, Eyck von der Heyde, Steffi Weniger, Martina Stauch
article en

Abstract

/µl). There was almost no difference in the total number of thromboembolic events in JAK inhibitor naïve versus JAK inhibitor pretreated patients (3.1%, n = 5 versus 3.8%, n = 10). No new safety concerns were observed with ruxolitinib. Findings from this study in a real-world setting show that ruxolitinib is an effective and safe second-line treatment in PV patients.

Annals of HematologyVol. 105(6)
University of Erfurt (DE), University of Würzburg (DE), Novartis (Germany) (DE), Thüringer Aufbaubank (DE), München Klinik (DE), Universitätsklinikum Würzburg (DE), Institut für Versorgungsforschung in der Onkologie (DE), Johannes Wesling Klinikum Minden (DE), Hannover Re (Germany) (DE), Minnesota Oncology (US)
Good health and well-being
Openalex Percentile: Top 5%
Myeloproliferative Neoplasms: Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera – German real-world data (PaVe study) — Martin Grießhammer, Rudolf Weide, et al. · Annals of Hematology (2026) | TGRS Research Map | TGRS